‘Landmark’ ovarian cancer treatment approved for NHS use

Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleThe National Institute for Health and Care Excellence (NICE) has approved a new treatment, mirvetuximab soravtansine (Elahere), for NHS use in women with hard-to-treat ovarian cancer. This marks the first new ovarian cancer treatment approved for NHS use in two decades, offering a lifeline to patients whose disease is resistant to chemotherapy. The targeted therapy, described as a “biological missile”, works by attaching to and destroying cancer cells, specifically for folate receptor-alpha-positive platinum-resistant epithelial cancers. Clinical trials indicate the drug can improve survival by approximately four months on average compared to chemotherapy alone, benefiting around 400 patients in England annually. Experts and patient advocates have hailed the “landmark” decision, highlighting its potential to significantly improve quality of life and provide additional options at a critical stage of the disease. In fullHundreds of women to benefit from breakthrough ovarian cancer treatment in UKThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in

Raccontata daindependent.co.uktheguardian.comdailymail.com